Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine

Clinical Pharmacokinetics

Volumn 42, Issue 11, 2003, Pages 985-996

  Kim, Myo Kyoung ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CIPROFLOXACIN; FLEROXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BODY WEIGHT; CAFFEINE; CIPROFLOXACIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLEROXACIN; HUMANS; MALE; SEX FACTORS;

EID: 0042856275     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342110-00004     Document Type: Article

References (14)

1. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995 Aug; 50 (2): 222-39
2. Bertino Jr JS, Nafziger AN. Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers. Antimicrob Agents Chemother 1996 Mar; 40 (3): 789-91
3. Sowinski KM, Abel SR, Clark WR, et al. Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy 1999 Apr; 19 (4): 442-6
4. Gallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol 1996 Nov; 42 (5): 632-4
5. LaCreta FP, Kollia GD, Duncan G, et al. Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 67S-75S
6. Harder S, Fuhr U, Staib AH, et al. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989 Nov 30; 87 (5A): 89S-91S
7. Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989 Apr; 33 (4): 474-8
8. Patel I, Holazo AA, Apostol L, et al. Caffeine-fleroxacin interaction in humans [abstract 423]. 3rd International Symposium on New Quinolones; 1990 Jul 12-14; Vancouver, Canada
9. Nicolau DP, Nightingale CH, Tessier PR, et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple-dose caffeine. Drugs 1995; 49 Suppl. 2: 357-9
10. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985 Oct; 28 (4): 581-6
11. Chin NX, Brittain DC, Neu HC. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother 1986 Apr; 29 (4): 675-80
12. Verbist L. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone. J Antimicrob Chemother 1987 Sep; 20 (3): 363-72
13. Balfour JA, Todd PA, Peters DH. Fleroxacin: a review of its pharmacology and therapeutic efficacy in various infections. Drugs 1995 May; 49 (5): 794-850
14. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996 Jun; 51 (6): 1019-74